4.6 Article

Malaria Inhibits Surface Expression of Complement Receptor 1 in Monocytes/Macrophages, Causing Decreased Immune Complex Internalization

Journal

JOURNAL OF IMMUNOLOGY
Volume 190, Issue 7, Pages 3363-3372

Publisher

AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.1103812

Keywords

-

Categories

Funding

  1. Ministerio de Ciencia e Innovacion, Spain
  2. National Institutes of Health [1 R56 AI070907-01A2, 3 R56 AI070907-01AS1]

Ask authors/readers for more resources

Complement receptor 1 (CR1) expressed on the surface of phagocytic cells binds complement-bound immune complexes (IC), playing an important role in the clearance of circulating IC. This receptor is critical to prevent accumulation of IC, which can contribute to inflammatory pathology. Accumulation of circulating IC is frequently observed during malaria, although the factors contributing to this accumulation are not clearly understood. We have observed that the surface expression of CR1 on monocytes/macrophages and B cells is strongly reduced in mice infected with Plasmodium yoelii, a rodent malaria model. Monocytes/macrophages from these infected mice present a specific inhibition of complement-mediated internalization of IC caused by the decreased CR1 expression. Accordingly, mice show accumulation of circulating IC and deposition of IC in the kidneys that inversely correlate with the decrease in CR1 surface expression. Our results indicate that malaria induces a significant decrease on surface CR1 expression in the monocyte/macrophage population that results in deficient internalization of IC by monocytes/macrophages. To determine whether this phenomenon is found in human malaria patients, we have analyzed 92 patients infected with either P. falciparum (22 patients) or P. vivax (70 patients), the most prevalent human malaria parasites. The levels of surface CR1 on peripheral monocytes/macrophages and B cells of these patients show a significant decrease compared with uninfected control individuals in the same area. We propose that this decrease in CR1 plays an essential role in impaired IC clearance during malaria. The Journal of Immunology, 2013, 190: 3363-3372.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Chemistry, Medicinal

Discovery of Potent N-Ethylurea Pyrazole Derivatives as Dual Inhibitors of Trypanosoma brucei and Trypanosoma cruzi

Swapna Varghese, Raphael Rahmani, Stephanie Russell, Girdhar Singh Deora, Lori Ferrins, Arthur Toynton, Amy Jones, Melissa Sykes, Albane Kessler, Amanda Eufrasio, Artur Torres Cordeiro, Julian Sherman, Ana Rodriguez, Vicky M. Avery, Matthew J. Piggott, Jonathan B. Baell

ACS MEDICINAL CHEMISTRY LETTERS (2020)

Article Infectious Diseases

Anti-ganglioside antibodies in patients with Zika virus infection-associated Guillain-Barre Syndrome in Brazil

Juan Rivera-Correa, Isadora Cristina de Siqueira, Sabrina Mota, Mateus Santana do Rosario, Pedro Antonio Pereira de Jesus, Luiz Carlos Junior Alcantara, Joel D. Ernst, Ana Rodriguez

PLOS NEGLECTED TROPICAL DISEASES (2019)

Article Chemistry, Medicinal

Discovery and Optimization of a Compound Series Active against Trypanosoma cruzi, the Causative Agent of Chagas Disease

Justin R. Harrison, Sandipan Sarkar, Shahienaz Hampton, Jennifer Riley, Laste Stojanovski, Christer Sahlberg, Pia Appelqvist, Jessey Erath, Vinodhini Mathan, Ana Rodriguez, Marcel Kaiser, Dolores Gonzalez Pacanowska, Kevin D. Read, Nils Gunnar Johansson, Ian H. Gilbert

JOURNAL OF MEDICINAL CHEMISTRY (2020)

Review Parasitology

Autoimmune Anemia in Malaria

Juan Rivera-Correa, Ana Rodriguez

TRENDS IN PARASITOLOGY (2020)

Article Chemistry, Medicinal

Scaffold and Parasite Hopping: Discovery of New Protozoal Proliferation Inhibitors

Baljinder Singh, Jean A. Bernatchez, Laura-Isobel McCall, Claudia M. Calvet, Jasmin Ackermann, Julia M. Souza, Diane Thomas, Everton M. Silva, Kelly A. Bachovchin, Dana M. Klug, Hitesh B. Jalani, Seema Bag, Melissa J. Buskes, Susan E. Leed, Norma E. Roncal, Erica C. Penn, Jessey Erath, Ana Rodriguez, Richard J. Sciotti, Robert F. Campbell, James McKerrow, Jair L. Siqueira-Neto, Lori Ferrins, Michael P. Pollastri

ACS MEDICINAL CHEMISTRY LETTERS (2020)

Article Infectious Diseases

Atypical memory B-cells and autoantibodies correlate with anemia during Plasmodium vivax complicated infections

Juan Rivera-Correa, Maria Fernanda Yasnot-Acosta, Nubia Catalina Tovar, Maria Camila Velasco-Pareja, Alice Easton, Ana Rodriguez

PLOS NEGLECTED TROPICAL DISEASES (2020)

Article Parasitology

Repurposing bioenergetic modulators against protozoan parasites responsible for tropical diseases

Alba Martinez-Florez, Melina Galizzi, Luis Izquierdo, Juan M. Bustamante, Ana Rodriguez, Fernando Rodriguez, Alheli Rodriguez-Cortes, Jordi Alberola

INTERNATIONAL JOURNAL FOR PARASITOLOGY-DRUGS AND DRUG RESISTANCE (2020)

Article Microbiology

Immune Response and Microbiota Profiles during Coinfection with Plasmodium vivax and Soil-Transmitted Helminths

Alice Easton, Mayra Raciny-Aleman, Victor Liu, Erica Ruan, Christian Marier, Adriana Heguy, Maria Fernanda Yasnot, Ana Rodriguez, P'ng Loke

Article Chemistry, Medicinal

Design, synthesis, and evaluation of substrate - analogue inhibitors of Trypanosoma cruzi ribose 5-phosphate isomerase type B

Soledad Natalia Gonzalez, Jonathan J. Mills, Dante Maugeri, Christopher Olaya, Breana L. Laguera, Jeffrey R. Enders, Julian Sherman, Ana Rodriguez, Joshua G. Pierce, Juan Jose Cazzulo, Edward L. D'Antonio

Summary: The study discovered a competitive inhibitor Compound B targeting ribose 5-phosphate isomerase type B (RPI-B), which exhibited significant trypanocidal activity against T. cruzi infective life-stages. By targeting the active site residue Cys-69, this inhibitor provided a proof-of-concept for the development of next generation inhibitors with potential prodrug groups to treat Chagas' disease in the future.

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2021)

Article Biochemistry & Molecular Biology

Anti-Trypanosoma cruzi Activity of Metabolism Modifier Compounds

Nieves Martinez-Peinado, Clara Martori, Nuria Cortes-Serra, Julian Sherman, Ana Rodriguez, Joaquim Gascon, Jordi Alberola, Maria-Jesus Pinazo, Alheli Rodriguez-Cortes, Julio Alonso-Padilla

Summary: The study found that 17-DMAG has a strong inhibitory effect on T. cruzi, particularly during the intracellular replicative stage of the parasite. Molecular docking results suggest that 17-DMAG may bind T. cruzi Hsp90 homologue Hsp83 with good affinity. However, evaluation in a mouse model of chronic T. cruzi infection did not show parasite growth inhibition, highlighting challenges in transitioning from in vitro assays to preclinical drug development stages.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Article Microbiology

Identification of Trypanosoma cruzi Growth Inhibitors with Activity In Vivo within a Collection of Licensed Drugs

Nieves Martinez-Peinado, Nuria Cortes-Serra, Julian Sherman, Ana Rodriguez, Juan M. Bustamante, Joaquim Gascon, Maria-Jesus Pinazo, Julio Alonso-Padilla

Summary: Chagas disease, caused by the parasite Trypanosoma cruzi, has its greatest burden in Latin America. Existing treatments present toxicity and variable efficacy, highlighting the urgent need for new therapeutic strategies. Drug repositioning offers a fast and low-cost approach to identify safer and more effective chemotherapies for Chagas disease.

MICROORGANISMS (2021)

Article Chemistry, Medicinal

Synthesis, biochemical, and biological evaluation of C2 linkage derivatives of amino sugars, inhibitors of glucokinase from Trypanosoma cruzi

Scott B. Green, Robert J. Lanier Jr, Shane M. Carey, David R. Morgan, Hanna Gracz, Julian Sherman, Ana Rodriguez, Edward L. D'Antonio

Summary: The screening of eighteen amino sugar analogues against Trypanosoma cruzi glucokinase revealed five on-target confirmed inhibitors, all from the D-GlcN series. Four of these compounds were identified as strong TcGlcK inhibitors, while three showed significant in vitro anti-T. cruzi activity. Compounds 5 and 6 were further evaluated biochemically, with formal Ki values determined and exhibiting competitive inhibition mode for TcGlcK.

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2021)

Letter Respiratory System

Autoimmunity to annexin A2 predicts mortality among hospitalised COVID-19 patients

Marisol Zuniga, Claudia Gomes, Steven E. Carsons, Michael T. Bender, Paolo Cotzia, Qing Robert Miao, David C. Lee, Ana Rodriguez

EUROPEAN RESPIRATORY JOURNAL (2021)

Article Infectious Diseases

Autoimmunity to phosphatidylserine and anemia in African Trypanosome infections

Juan Rivera-Correa, Joseph Verdi, Julian Sherman, Jeremy M. Sternberg, Jayne Raper, Ana Rodriguez

Summary: The study found evidence of autoimmunity against phosphatidylserine in Trypanosoma brucei infected mice and Human African Trypanosomiasis patients, suggesting a potential link between autoimmunity and anemia.

PLOS NEGLECTED TROPICAL DISEASES (2021)

Article Medicine, Research & Experimental

Endothelial transcriptomic analysis identifies biomarkers of severe and cerebral malaria

Claudia Gomes, Rosauro Varo, Miquel Duran-Frigola, Antonio Sitoe, Rubio Bila, Sonia Machevo, Alfredo Mayor, Quique Bassat, Ana Rodriguez

Summary: Malaria can progress from an uncomplicated infection to a life-threatening severe disease. Early symptoms are often nonspecific, making it difficult to identify patients at high risk. By analyzing the transcriptomic response of human brain microvascular endothelial cells to Plasmodium falciparum-infected erythrocytes, several biomarkers have been identified to distinguish uncomplicated from severe malaria, as well as to differentiate children with cerebral malaria within the severe malaria group.

JCI INSIGHT (2023)

No Data Available